Sharemaestro Newsreel

Tempus AI buys Personalis for $1.7B as digital health M&A su

Tempus AI's acquisition of Personalis for $1.7 billion signals a significant consolidation trend in health-tech amid a surge in M&A and venture capital activities, with $7.4 billion in funding during the first half of 2026. This trend is reshaping vendor choices for health system …

Earnings Beat: OPKO Health, Inc. (NASDAQ:OPK) Just Beat Analyst Forecasts, And Analysts Have Been Lifting Their Forecasts

OPKO Health, Inc. recently reported a significant earnings beat, surpassing analyst revenue and statutory EPS forecasts. Following these results, analysts have raised their revenue and EPS estimates for the company's future performance, suggesting a more optimistic outlook. The revised forecasts indicate a positive sentiment …

Earnings call transcript: Labcorp tops Q2 2026 estimates, lifts full-year outlook

Labcorp exceeded Q2 2026 estimates with strong revenue and adjusted EPS, leading to a lifted full-year outlook. The company reported adjusted EPS of $4.99 and revenue of $3.73 billion, driven by solid organic growth, margin expansion, and strong performance in specialty testing and biopharma …

Adaptive Biotechnologies stock hits 52-week high at 23.25 USD

Adaptive Biotechnologies (ADPT) stock reached a 52-week high of $23.25, reflecting a significant 120.31% increase over the past year. Despite its robust revenue growth of 56% over the last twelve months, InvestingPro analytical data suggests the stock might be overvalued. Recent Q2 results showed …

Natera executive chairman sells $447k in shares

Matthew Rabinowitz, Executive Chairman and Director of Natera, Inc. (NASDAQ:NTRA), sold 1,718 shares for $447,523 to cover tax obligations related to restricted stock units. This sale comes as Natera shares have risen 80% over the past year, though InvestingPro suggests the stock is overvalued. …

Natera, Inc. (NTRA) CFO disposes of 5,064 shares in 10b5-1 trades

Natera, Inc.'s CFO, Brophy Michael Burkes, sold a total of 5,064 shares of common stock between July 27-29, 2026, through open-market transactions. These sales, executed under a Rule 10b5-1 trading plan adopted in 2025, included shares sold to cover tax withholding obligations related to …

Medpace Holdings President & CEO Trades $4.35M In Company Stock

Medpace Holdings's President & CEO, August J Troendle, sold 7,238 shares of company stock worth $4.35 million on July 29, 2026, according to an SEC filing. Despite this insider sale, the company reported strong revenue growth of 17.24% for the quarter ending June 30, …

Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%

Myriad Genetics (NASDAQ:MYGN) reported Q2 CY2026 sales of $190.7 million, falling short of analyst estimates, and a non-GAAP loss of $0.25 per share, significantly below consensus. The company also lowered its full-year revenue guidance to $780 million at the midpoint from an earlier $870 …

CareDx, Inc. 2Q 2026: Revenue $131.95M, EPS $2.07— 10-Q Summary

CareDx, Inc. (CDNA) reported strong second-quarter 2026 results with revenue of $131.95 million and diluted EPS of $2.07. This performance was significantly boosted by higher testing services volume, prior-period collections, and a one-time gain of approximately $113 million from the sale of its lab …

Veracyte (VCYT) Rises with Upward Guidance Revision and Earnings Beat

Veracyte, Inc. (VCYT) saw its shares advance significantly during Q2 2026 due to a strong earnings beat and raised full-year guidance, driven by double-digit volume growth in its Decipher test and improved Afirma performance. Meridian Small Cap Growth Fund highlighted VCYT as a key …

Labcorp (LH) Reports Q2 Earnings: What Key Metrics Have to Say

Labcorp Holdings (LH) reported $3.73 billion in revenue for the quarter ended June 2026, representing a year-over-year increase of 5.8%. EPS of $4.99 for the same period compares to $4.35 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $3.72 …

OPKO Health FY2026 EPS Estimate Increased by HC Wainwright

HC Wainwright has increased its FY2026 EPS estimate for OPKO Health to a loss of $0.23 per share from $0.30, while maintaining a "Buy" rating. This upgrade follows OPKO's recent quarterly results, which surpassed expectations with a $0.01-per-share loss against an estimated $0.08 loss …

ICON (ICLR) Is Up 6.5% After Reaffirming 2026 Outlook And Announcing Anthropic AI Deal – Has The Bull Case Changed?

William Blair Initiates Icon PLC(ICLR.US) With Buy Rating

William Blair has initiated coverage on Icon PLC (ICLR.US) with a Buy rating. This indicates a positive outlook from the investment firm regarding the company's stock performance.

Labcorp (NYSE:LH) Reports Q2 CY2026 In Line With Expectations

Labcorp (NYSE:LH) reported Q2 CY2026 results, meeting revenue expectations with $3.73 billion and beating adjusted EPS estimates at $4.99 per share. The company slightly increased its full-year revenue and Adjusted EPS guidance, demonstrating continued momentum despite a slight post-earnings stock dip. While long-term revenue …

Labcorp raises annual profit forecast on strong testing demand

By Sahil Pandey July 30 (Reuters) - Laboratory operator Labcorp raised its annual profit forecast and posted better-than-expected second-quarter results on Thursday, ‌as steady demand for diagnostic testing and growth in ‌its drug-development services business boosted performance. Shares of the company fell about 6% …

Icon PLC (ICLR) Shares Fall 7.1% -- What GF Score of 88 Tells In

Icon PLC (ICLR) shares recently fell 7.1% to $165.53, yet the company holds a strong GF Score of 88/100, indicating solid fundamentals and growth potential. Despite a high historical P/E, ICLR is considered "modestly undervalued" by GuruFocus, with a GF Value of $227.59, suggesting …

Deutsche Bank Downgrades Option Care Health to Hold From Buy, Adjusts PT to $24 From $26

Deutsche Bank has downgraded Option Care Health (OPCH) from a "Buy" rating to "Hold" and reduced its price target from $26 to $24. This action indicates a revised outlook on the stock's performance. Previously, Stephens also downgraded Option Care to "Equal Weight" from "Overweight" …

XWELL Inc. Q3 2023 Earnings: Losses Widen Sharply, Stock Declines - Dividend Growth Analysis

Prenetics (NASDAQ: PRE) updates Hong Kong risk, Bitcoin treasury

Prenetics (NASDAQ: PRE) has filed an amendment to its 2025 annual report, clarifying its holding-company structure, intra-group cash flows, non-IFRS indicators, and risks associated with Hong Kong and the PRC. The company also disclosed substantial net losses from 2023-2025 due to marketing investments for …

IQVIA Stock Climbs 25% On A 5-Day Winning Streak

IQVIA (IQV) stock has experienced a significant surge, climbing 25% over five consecutive trading days, adding $8.1 billion to its market value. This strong performance, which outpaced the S&P 500's decline during the same period, is supported by the company's slightly faster-than-market revenue growth …

Bacterial Vaginosis Linked to Increased STI Co-Infection, Finds National Study of 1.5 Million Women from Quest Diagnostics

A national Health Trends® study by Quest Diagnostics and Hologic, Inc. found that women testing positive for bacterial vaginosis (BV) were over three times more likely to also have non-viral sexually transmitted infections (STIs). The study, which analyzed data from 1.5 million women between …

Bacterial vaginosis patients were over 3x more likely to have an STI

A national study by Quest Diagnostics and Hologic, analyzing data from over 1.5 million U.S. women, found that 12% of women positive for bacterial vaginosis (BV) also had at least one non-viral sexually transmitted infection (STI), compared to 3.8% of BV-negative women. BV positivity …

Thermo Fisher Scientific Inc (TMO) pairs a 6.7% week with elevated volume

The diagnostics and research supplier is extending a three-month advance, though the trend screen has not turned active.

Levi & Korsinsky Reminds Grail, Inc. Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of August 4, 2026 - GRAL

Levi & Korsinsky, LLP has filed a securities class action lawsuit against Grail, Inc. (NASDAQ: GRAL), reminding investors who purchased stock between May 13, 2025, and February 19, 2026, of the August 4, 2026 lead plaintiff deadline. The lawsuit alleges that Grail's leadership withheld …

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

Guardant Health (GH) reported a Q2 loss of $0.42 per share, which was worse than the Zacks Consensus Estimate of a $0.40 loss, but its revenues of $334.98 million surpassed estimates by 6.01%. Despite outperforming the market year-to-date, the stock currently holds a Zacks …

Labcorp posts Q2 revenue $3.73B, adjusted EPS $4.99; raises 2026 guidance

Labcorp reported strong second-quarter 2026 results, with revenue of $3.73 billion and adjusted diluted EPS of $4.99, marking a 14.9% year-over-year increase. The company raised its full-year 2026 guidance for both enterprise revenue growth and adjusted EPS, and announced a $1.0 billion increase in …

Icon Q1 2026 Earnings Call Transcript

ICON reported strong Q1 2026 financial results, with gross bookings up 22% year-over-year and net business wins of $2.88 billion. The company reaffirmed its full-year 2026 guidance for revenue and adjusted diluted EPS, expecting modest sequential margin improvement. Strategic investments in central labs, oncology …

Labcorp Q2 Revenue Rises 5.8 Percent to $3.73 Billion

Labcorp (LH) reported a 5.8% increase in second-quarter 2026 revenue to $3.73 billion, with diluted EPS rising to $3.64. The company raised its full-year revenue and adjusted EPS guidance and announced a $1.0 billion increase in its share repurchase authorization. Insider trading data shows …

Labcorp Announces 2026 Second Quarter Results; Raises Full Year 2026 Guidance

Labcorp reported strong second-quarter 2026 results with 6% revenue growth, significant margin expansion, and double-digit adjusted EPS growth. The company raised its full-year 2026 guidance, reflecting continued momentum in its business operations. Key strategic advancements include expanding oncology offerings, strengthening partnerships with health systems, …

Prenatal and Reproductive Genetic Testing Market Size & Share 2026-2035

The global prenatal and reproductive genetic testing market was valued at USD 7.8 billion in 2025 and is projected to reach USD 22.4 billion by 2035, growing at a CAGR of 11.2%. This growth is driven by increasing demand for early genetic risk assessment, …

Labcorp Holdings earnings beat by $0.20, revenue topped estimates

Labcorp Holdings (LH) reported second-quarter EPS of $4.99, exceeding analyst estimates by $0.20, and revenue of $3.73 billion, surpassing the consensus of $3.71 billion. The company also provided a positive FY 2026 EPS guidance of $18.10-$18.55, higher than the analyst consensus. Labcorp's stock has …

Revvity (RVTY) Stock Could Be 22% Undervalued As Cash Flow Supports A Bargain

Revvity's stock valuation shows a mixed picture: a Discounted Cash Flow (DCF) analysis suggests it could be 22% undervalued, implying an intrinsic value of $145 per share, while its P/E ratio of 52.9x indicates overvaluation compared to the industry average. The company's share price …

MONDAY DEADLINE: GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit - WGS

Robbins Geller Rudman & Dowd LLP announces a lead plaintiff deadline of Monday, August 3, 2026, for investors who purchased GeneDx Holdings Corp. (NASDAQ: WGS) common stock between April 16, 2025, and May 4, 2026. The lawsuit alleges that GeneDx made false or misleading …

CareDx Number of Employees 2026 | Employee Count & Headcount Data

CareDx, Inc. (CDNA) had approximately 805 total employees worldwide as of March 2026, marking a 14.9% growth from 700 employees in 2023. The company is actively hiring, with 92 active job postings in 2026, though this represents a 28.0% decline from 2025. CareDx's workforce …

QUEST DIAGNOSTICS INC : JP MORGAN RAISES TARGET PRICE TO $250 FROM $220

JP Morgan has increased its target price for Quest Diagnostics Inc. from $220 to $250. This change in target price suggests an updated positive outlook for the company's stock by the financial institution. The specific reasons for this revised target are not detailed in …